ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

• Published in: Modern pathology Vol. 25; no. 3; pp. 471 - 479
• Main Authors: Hoogland, A Marije, Jenster, Guido, van Weerden, Wytske M, Trapman, Jan, van der Kwast, Theo, Roobol, Monique J, Schröder, Fritz H, Wildhagen, Mark F, van Leenders, Geert JLH
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.03.2012; Elsevier Limited
• Subjects: Adenocarcinoma; Adenocarcinoma - metabolism; Adenocarcinoma - mortality; Adenocarcinoma - surgery; Aged; Androgen receptors; Androgens; Antigens; Biomarkers, Tumor - metabolism; DNA microarrays; ERG gene; ERG protein; ETS protein; Gene fusion; gene rearrangement; Genes; genomics; Humans; Immunohistochemistry; Laboratory Medicine; Male; Medical screening; Medicine; Medicine & Public Health; Middle Aged; Multivariate analysis; Neoplasm Recurrence, Local - diagnosis; original-article; Pathology; Patients; Polymerase chain reaction; Predictive Value of Tests; Prognosis; Prostate cancer; prostate-specific antigen; Prostate-Specific Antigen - blood; Prostatectomy; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - mortality; Prostatic Neoplasms - surgery; Protein expression; Proteinase; Proteins; Receptors, Androgen - metabolism; Serine; Survival; Survival Rate; Trans-Activators - metabolism; Transcription factors; Transcriptional Regulator ERG; Tumors; Ultrasonic imaging; Xenografts; Netherlands; recurrence; progression; prostate cancer; ERG; immunohistochemistry
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1038/modpathol.2011.176

In prostate cancer genomic rearrangements involving genes encoding ETS transcription factors are commonly present, with androgen-regulated transmembrane protease , serine 2 (TMPRSS2)-v-ets erythroblastosis virus E26 oncogen homologue (ERG) gene fusion occurring in 40–70%. Studies on the predictive value of ERG rearrangement as detected by in-situ hybridization or polymerase chain reaction have resulted in varying outcomes. The objective of this study was to correlate immunohistochemical ERG protein expression with clinico-pathological parameters at radical prostatectomy specimens, and to determine its predictive value for postoperative disease recurrence and progression in a prostate cancer screening cohort. Since androgen receptor is downregulated by ERG in cell lines, we also compared the expression of respective proteins. We selected 481 participants from the European Randomized Study of Screening for Prostate Cancer treated by radical prostatectomy for prostate adenocarcinoma. A tissue microarray was constructed containing representative cores of all prostate cancer specimens as well as 22 xenografts and seven cell lines. Immunohistochemical expression of ERG and androgen receptor was correlated with prostate-specific antigen (PSA), Gleason sum, pT-stage, surgical margins, biochemical recurrence, local recurrence, overall death and disease-specific death. ERG expression was detected in 284 patients (65%). Expression occurred significantly more frequent in patients with PSA ≤10 ng/ml ( P =0.024). There was no significant association between ERG and Gleason sum, pT-stage or surgical margin status. PSA ( P =0.011), Gleason sum ( P =0.003), pT-stage ( P =0.001) and surgical margin status ( P <0.001) all had independent value for postoperative biochemical recurrence, while positive surgical margin ( P =0.021) was the only independent predictor for local recurrence. ERG protein expression did not have prognostic value for the clinical end points in uni- and multivariate analyses. A positive correlation existed between ERG and androgen receptor expression in single tissue cores ( P <0.001). In conclusion, immunohistochemical ERG expression has no predictive value for prostate cancer recurrence or progression after radical prostatectomy. Increasing ERG levels are associated with the upregulation of androgen receptor expression in clinical specimens.